The grant of a key patent in Europe for the use of ridinilazole for the treatment of C. difficile infection strengthens the group’s IP portfolio and follows the US grant of the patent in May 2015. C. difficile infection is established as a major healthcare threat, with around 900,000 cases per annum in Europe and North America. Recurrent disease represents a key clinical issue with around 30% of patients at risk of recurrent disease after the initial episode. Ridinilazole met its primary objective in a Phase II trial in November, demonstrating a superior sustained clinical response to standard treatment. Summit is currently evaluating all options for progressing ridinilazole into Phase III trials and we look forward to an update in due course. We remain positive on the group’s future prospects.
